APA-viite

Pirilä, L. J., Nordstrom, D., Valleala, H., Joensuu, J. T., Aaltonen, K. J., Virkki, L., . . . Pirilä, L. (2015). Rates of Serious Infections and Malignancies Among Patients with Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy. Journal of Rheumatology.

Chicago-tyylinen lähdeviittaus

Pirilä, Laura Johanna, et al. "Rates of Serious Infections and Malignancies Among Patients With Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy." Journal of Rheumatology 2015.

MLA-viite

Pirilä, Laura Johanna, et al. "Rates of Serious Infections and Malignancies Among Patients With Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy." Journal of Rheumatology 2015.

Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.